Gensight Biologics (FRA:G49N) EBITDA Margin %: -1,456.36% (As of Dec. 2025)


What is Gensight Biologics EBITDA Margin %?

Gensight Biologics FRA:G49N -0.41% EBITDA Margin % is -1,456.36% as of Dec. 2025. The stock has 8 warning signs investors should review. Among 943 Biotechnology companies, Gensight Biologics ranks worse than 99.79% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gensight Biologics's EBITDA for the six months ended in Dec. 2025 was €-3.20 Mil. Gensight Biologics's Revenue for the six months ended in Dec. 2025 was €0.22 Mil. Therefore, Gensight Biologics's EBITDA margin for the quarter that ended in Dec. 2025 was -1,456.36%.

Gensight Biologics  (FRA:G49N) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Gensight Biologics EBITDA Margin % Related Terms

Gensight Biologics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Gensight Biologics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gensight Biologics EBITDA Margin % Chart

Gensight Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -483.72 -925.95 -1,648.78 -757.93 -868,800.00

Gensight Biologics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,862.19 -466.97 -1,523.73 2,504.11 -1,456.36

FRA:G49N vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Gensight Biologics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gensight Biologics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's EBITDA Margin % falls into.


Gensight Biologics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Gensight Biologics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-8.688/0.001
=-868,800.00 %

Gensight Biologics's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-3.204/0.22
=-1,456.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -1,456.36% mean?
Gensight Biologics (FRA:G49N) has a EBITDA Margin % of -1,456.36% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gensight Biologics and its competitors. According to the industry distribution chart, Gensight Biologics ranks #941 out of 943 companies in the Biotechnology industry, placing it in the top 99.8%.
Is Gensight Biologics' EBITDA Margin % too high?
Gensight Biologics' current EBITDA Margin % is -1,456.36%. Based on the distribution chart, Gensight Biologics ranks #941 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Gensight Biologics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #941 out of 943 companies for EBITDA Margin %. This places Gensight Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gensight Biologics and its competitors. Gensight Biologics's current EBITDA Margin % is -1,456.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (FRA:G49N) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.07 — trading 82% above its estimated fair value. The current EBITDA Margin % is -1,456.36%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gensight Biologics (FRA:G49N), the current EBITDA Margin % is -1,456.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gensight Biologics Business Description

Address 74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.